Natalie S. Callander

University of Wisconsin Carbone Cancer Center

Also affiliated with University of Wisconsin Health

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 26 papers. Top paper: “Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)”.

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

Blood Cancer Journal(2021)10.1038/s41408-021-00494-4

N/A

4.4DataRank · unranked

88 citations

Ajay K. Nooka, Praneetha Thulasi, Ashraf Badros, Bennie H. Jeng, Natalie S. Callander +15 more

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30354-9

N/A

3.8DataRank · unranked

126 citations

Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Sandi Hita +12 more

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.18_suppl.lba3

N/A

0DataRank · unranked

31 citations

Susanna Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, Avina A. Singh +15 more

Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8507

N/A

0DataRank · unranked

26 citations

Sikander Ailawadhi, Rachael Sexton, Antje Hoering, Brea Lipe, Sandi Hita +9 more

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study

UNC Libraries(2020)10.17615/0d7e-cz27

N/A

0DataRank · unranked

0 citations

Robert A. Kyle, Heather J. Landau, Siddhartha Ganguly, Anita D’Souza, Brendan M. Weiss +25 more

Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.08.010

N/A

0DataRank · unranked

29 citations

Natalie S. Callander, Aric C. Hall, Mei-Jei Zhang, Khalid Bo-Subait, Hailin Wang +43 more

Timelapse viability assay to detect division and death of primary multiple myeloma cells in response to drug treatments with single cell resolution

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.11.12.467843

N/A

0DataRank · unranked

0 citations

Natalie S. Callander, Kenny Chng, Shigeki Miyamoto, Jay W. Warrick, Christina Mark

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Blood Cancer Journal(2022)10.1038/s41408-022-00695-5

N/A

0DataRank · unranked

61 citations

Lawrence Baizer, Natalie S. Callander, Sergio Giralt, Jens Hillengaß, Boris Freidlin +11 more

Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma

American Journal of Hematology(2022)10.1002/ajh.26596

N/A

0DataRank · unranked

30 citations

Ruta Brazauskas, Edward A. Stadtmauer, Marcelo C. Pasquini, Parameswaran Hari, Asad Bashey +16 more

Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model

Scientific Reports(2022)10.1038/s41598-022-14114-z

N/A

0DataRank · unranked

15 citations

Zhi Wen, Adhithi Rajagopalan, Oisun Jung, Lyndsay Watkins, Joshua Wiesner +10 more

A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance

Molecular Cancer Research(2022)10.1158/1541-7786.mcr-21-0941

N/A

0DataRank · unranked

13 citations

Jay W. Warrick, Natalie S. Callander, Peiman Hematti, Shigeki Miyamoto, Christina Mark

A biobehavioral intervention to enhance recovery following hematopoietic cell transplantation: Protocol for a feasibility and acceptability randomized control trial

Contemporary Clinical Trials Communications(2022)10.1016/j.conctc.2022.100938

N/A

0DataRank · unranked

4 citations

Meredith E. Rumble, Lisa Cadmus‐Bertram, Mark Juckett, Paul J. Rathouz, Gwynneth Schell +4 more

HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs

PLoS ONE(2022)10.1371/journal.pone.0274704

N/A

0DataRank · unranked

4 citations

Hae Yeun Chang, Dominique N. Lisiero, Irene M. Ong, Trinayan Kashyap, Natalie S. Callander +2 more

Timelapse viability assay to detect division and death of primary multiple myeloma cells in response to drug treatments with single cell resolution

Integrative Biology(2022)10.1093/intbio/zyac006

N/A

0DataRank · unranked

1 citations

Natalie S. Callander, Kenny Chng, Shigeki Miyamoto, Jay W. Warrick, Christina Mark

Perturbation of the Gut Microbiome and Association with Outcomes Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

medRxiv(2022)10.1101/2022.05.19.22275261

N/A

0DataRank · unranked

4 citations

Sailendharan Sudakaran, Fotis Asimakopoulos, Peiman Hematti, Dalia El‐Gamal, Nasia Safdar +2 more

Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.8054

N/A

0DataRank · unranked

4 citations

Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Jason Valent +11 more

Inflammatory CD4/CD8 double positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.01.11.475845

N/A

0DataRank · unranked

3 citations

David P Turicek, Jeremiah Riendeau, Sean J. McIlwain, Emmanuel Contreras Guzman, Kalyan Nadiminti +7 more

Ponatinib for RAS-Driven Multiple Myeloma: Efficacy in the High-Risk VQ Myeloma Model

Research Square(2022)10.21203/rs.3.rs-1296881/v1

N/A

0DataRank · unranked

0 citations

Zhi Wen, Adhithi Rajagopalan, Oisun Jung, Joshua Wiesner, Xiaona You +8 more

Genomic and transcriptional profiling stratifies VQ myeloma lines into two clusters with distinct risk signatures and drug responses

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.08.21.504657

N/A

0DataRank · unranked

0 citations

Mei Yu, Adhithi Rajagopalan, Yun Zhou, Yubin Feng, Anthony J. Veltri +9 more

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

Science Advances(2023)10.1126/sciadv.adf0567

N/A

0DataRank · unranked

32 citations

David P Turicek, Jeremiah Riendeau, Sean J. McIlwain, Emmanuel Contreras Guzman, Kalyan Nadiminti +7 more

Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses

Oncogene(2023)10.1038/s41388-023-02684-9

N/A

0DataRank · unranked

5 citations

Mei Yu, Govinda Poudel, Anthony J. Veltri, Yun Zhou, Adhithi Rajagopalan +10 more

HAPLN1 matrikine: a bone marrow homing factor linked to poor outcomes in patients with MM

Blood Advances(2023)10.1182/bloodadvances.2023010139

N/A

0DataRank · unranked

5 citations

Mailee Huynh, Avtar Roopra, Natalie S. Callander, Shigeki Miyamoto, Hae Yeun Chang

Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial

Research Square(2023)10.21203/rs.3.rs-3318127/v1

N/A

0DataRank · unranked

1 citations

Jeries Kort, Leland Metheny, Pingfu Fu, Parameswaran Hari, Gen Li +8 more

Data from Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells

(2023)10.1158/1541-7786.c.6542187.v1

N/A

0DataRank · unranked

0 citations

Natalie S. Callander, Shelby L. O’Connor, Jihoon Kim, Jae Werndli, Martha Raschko +5 more

Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial

Transplantation and Cellular Therapy(2024)10.1016/j.jtct.2024.01.053

N/A

0DataRank · unranked

4 citations

Jeries Kort, Leland Metheny, Pingfu Fu, Gen Li, Parameswaran Hari +8 more

Expression of Nras Q61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice

Blood(2020)10.1182/blood.2020007156

N/A

0DataRank · unranked

44 citations

Adhithi Rajagopalan, Evan Flietner, Grant Yun, Marta Chesi, Quinlan Furumo +20 more